KalVista Pharmaceuticals (KALV) Net Income Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 12.59% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -115.33% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -73.01% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,228.66% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -48.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -48.70% |
| Apr 30, 2025 | 34.35% |
| Oct 31, 2024 | -53.45% |
| Jul 31, 2024 | -43.57% |
| Apr 30, 2024 | 194.87% |
| Jan 31, 2024 | -10.74% |
| Oct 31, 2023 | -13.90% |
| Jul 31, 2023 | -8.04% |
| Apr 30, 2023 | -16.49% |
| Jan 31, 2023 | 0.80% |
| Oct 31, 2022 | -9.10% |
| Jul 31, 2022 | -35.51% |
| Apr 30, 2022 | -49.72% |
| Jan 31, 2022 | -111.06% |
| Oct 31, 2021 | -85.20% |
| Jul 31, 2021 | -35.66% |
| Apr 30, 2021 | -106.28% |
| Jan 31, 2021 | -1.36% |
| Oct 31, 2020 | -43.31% |
| Jul 31, 2020 | -58.06% |
| Apr 30, 2020 | 21.00% |
| Jan 31, 2020 | -108.05% |
| Oct 31, 2019 | -87.33% |
| Jul 31, 2019 | -29.68% |
| Apr 30, 2019 | -274.62% |
| Jan 31, 2019 | -37.05% |
| Oct 31, 2018 | 21.01% |
| Jul 31, 2018 | -26.95% |
| Apr 30, 2018 | 42.85% |
| Jan 31, 2018 | 46.58% |
| Oct 31, 2017 | -47.85% |
| Jul 31, 2017 | -6.76% |
| Mar 31, 2016 | -27.39% |
| Sep 30, 2015 | -27.22% |
| Jun 30, 2015 | -131.69% |
| Mar 31, 2015 | -157.27% |